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ABSTRACT 
 Cancer research is a large topic in science, because over 14 million people are diagnosed 
worldwide, and of those, 8 million will die annually. Traditional therapies are the mainstays of treatment 
strategies, but a cure less invasive or with less side effects have not yet been identified. In order to 
develop a better cure, we need to understand the tumor and molecules present in its tissues. Integrins, cell 
surface proteins that aid in cell communication, have been found in the tumor tissues of several types of 
cancers, including prostate, lung and bone. Integrin alpha-6 (ITGA6), in particular, has been found to 
have a large effect on the progression of tumor metastasis. In tumor tissues, we have seen an 
overexpression of the ITGA6 that leads to tumor metastasis and overall tumor progression. We have also 
seen an in vitro cleaving mechanism, in which only a cleaved, or extracellular portion of the protein is 
expressed in the microenvironment. To develop a therapeutic strategy, it is important to understand the 
role of ITGA6 in tumor development. Using a humanized zebrafish model, we hypothesized that 
increasing ITGA6 and cleaving ITGA6 will increase tumor metastasis. To study this question, we 
overproduced ITGA6 by injecting human ITGA6 RNA and reduced the gene using the morpholinos. We 
also injected cleaved human ITGA6 RNA and non-cleaved, or mutated ITGA6 RNA that could be not 
removed from the surface of the cell. We then injected human prostate cancer cells and allowed a human 
tumor microenvironment to develop over two days. Using confocal imaging, we visualized non-metastatic 
versus metastatic embryos. We utilized a t-test and found p-values of <.01 when comparing the full length 
ITGA6 and cleaved ITGA6 to the control. We concluded that increased and cleaved integrin alpha 6 
allow for the cell to develop cancerous abilities such as increased aggressiveness, motility through the 
ECM, invasion and metastasis in blood vessels to create secondary tumors. Studies are now showing that 
ITGA6 can be used a biomarker, a molecule that can predict the susceptibility of several cancers. In the 
future, we would like to use ITGA6 manipulations and drug screenings in a favorable zebrafish model to 
create a preventative strategy for cancer. 
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 Introduction 
1. Cancer 
Cancer is the foremost generic word that creates severe panic within a person, family, or 
community. Cancer [Figure 1] is defined as a disease characterized by abnormal growth of cells 
due to uncontrollable cell division. It can be 
caused by external factors that include 
one’s behavior such as smoking, drinking, 
diet, and exercise. It can also be caused by 
internal factors such as genetics, hormones, 
and immune conditions (1).  This panic is 
supported by the gruesome reality of cancer 
with approximately 14 million people being 
diagnosed worldwide each year (2,3). Of 
those diagnosed, over 50% of these cases 
come from undeveloped countries. The most 
prominent types of cancer include lung, 
female breast, bowel and prostate cancer, 
with 4 in 10 cases stemming from one of 
these groups (3). Of those diagnoses, over 
half, 8 million, will die. Most deaths come from lung, liver, bowel, and stomach cancer, with 
lung cancer accounting for one-fifth of all deaths (3).  In the female population, breast cancer is 
the most deadly. Approximately 240,000 new cases will be diagnosed in women, and 40,000 
women will die (2). Prostate cancer, however, is very prevalent in males, being the second most 
Figure 1. This schematic shows the overall progression 
of tumor development, where a cancer cell loses 
adhesion to the tissue. The cell invades and 
metastasizes into the blood vessels creating secondary 
tumors. 
http://www.nature.com/nrc/journal/v5/n1/images/nrc1527-
f4.jpg 
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common cancer in males after skin cancer.  In the United States, there are approximately 230,000 
new cases each year and over 3 million people living with the cancer today (2). The death rate of 
prostate cancer is one of the most with about 12% (1 in 38) of all diagnoses ending fatally (1).  
1.1 Cancer Management 
In order to have the best chances of managing a patient’s cancer, early diagnosis and 
appropriate therapeutic strategies are the two major steps to effectively fight the disease (4).  
Early diagnosis of the cancer gives a better chance of it not already becoming too big or 
spreading to other vital organs (4). An important tool in early diagnosis is the use of biomarkers. 
Biomarkers are any substance or molecule that can indicate the presence of cancer in the body 
(4). In addition to early diagnosis, it is vital to use the most appropriately fitting therapeutic 
strategy to treat the three factors that cause cancer to be so difficult to control. 
1.2 Three Factors of Cancer: Angiogenesis, Metastasis, and Cancer Stem Cells 
First, angiogenesis occurs in a patient. Angiogenesis [Figure 2] is the creation of blood 
vessels that stem from the tumor into the blood stream (5).  
These blood vessels allow the tumor to 
receive nutrients that are pertinent to 
its growth and survival. They are also 
Figure 2. Newly formed blood 
vessels are stemming from the tumor 
into the microenvironment created 
via angiogenesis.  
http://systemsbiology.case.edu/OLD%20
WEBSITE%20STUFF/images/angiogen
esis/angiogenesis_pic1.jpg 
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a pathway for the cancer cells of the tumor to travel through the bloodstream to reach other 
organs (5). 
 The dissemination of cancer cells [Figure 3] throughout the body using these blood 
vessels is known as metastasis, the second factor of cancer (6).   
Metastasis is the most deadly element of 
cancer as it 
is the cause 
of over 
90% of the 
deaths 
related to cancer. Once cancer cells reach other organs, 
they have the potential to create secondary tumors, facilitated by cancer stem cells, the third and 
least understood mechanism of cancer (6).  
 
 
Cancer stem cells (CSC) [Figure 4] are similar 
to normal, human 
stem cells, because 
they are self-renewing 
(7).    
Figure 3. The cells moving 
from the primary tumor into the 
blood stream via newly formed 
blood vessel into a previous 
blood vessel is the process 
known as metastasis that creates 
secondary tumors in another 
tissues. 
http://www.nature.com/nrc/journal/
v5/n1/images/nrc1527-f4.jpg 
 
 
 
Figure 4. The purple, orange, and 
pink cells signify cancer cells 
with variations. The green cells 
represent cancer stem cells that 
have the ability to form new 
tumor masses in different tissues. 
http://www.nature.com/labinvest/jour
nal/v91/n5/images/labinvest201150f1
.jpg 
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These cells originate from stem cells or progenitors, targeted stem cells specific to cancer (7,10). 
In a tumor, there can exist multiple populations of CSCs or they can co-exist among normal 
cancerous cells (10). CSCs can influence the start of metastasis, as well as, relapse in a patient 
that is in remission (10). 
1.3 Traditional Treatments 
Modern, conventional therapeutic strategies that try to control the factors of cancer 
include chemotherapy, radiation, and surgery. Chemotherapy uses anti-cancer drugs to shrink 
and eliminate the tumor (8). Radiation uses ionizing radiation to kill cancer cells by damaging 
their DNA (9). Surgery for cancer patients has a number of different uses, ranging from 
diagnostic to curative surgeries (10). Both chemotherapy and radiation have severe adverse 
effects, because the strategies are non-specific. They both kill all types of cells, which leads to 
severe damage in other vital tissues and organs (9,10). Surgery can and very often leads to 
deadly infections that can kill the patient (10). What all three therapeutic strategies have in 
common is that they aim to treat cancer, but they have no mechanism to cure the cancer (9,10). 
In order to have the best chance of curing any type of cancer, a molecule needs to exist that can 
be a biomarker, as well as, be used appropriately as a therapeutic strategy (10). Integrinα6 
(ITGA6) is a molecule that is a biomarker for several types of cancer and can potentially be used 
as a therapeutic strategy to treat cancer (10). 
2. Integrinα6 in Cancer 
2.1 ITGA6 Protein  
ITGA6 is a part of a group of transmembrane proteins that aid in cell adhesion, cell-to-
cell communication, intracellular communication, and act as ECM receptors that were 
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discovered approximately 25 years ago (11). These proteins are most notably known for binding 
to extracellular glycoproteins such as laminin, vascular cell adhesion molecule-1 and collagen, to 
enhance cell adhesion, proliferation, cell differentiation, and cell migration (11). Integrins are 
made of two subunits, alpha and beta, that are bound via noncovalent interactions to make 
heterodimeric proteins (6, 11). Integrins vary in size, depending on higher order function, and 
have been found in all mammals and most fish, such as sponges, nematodes, zebrafish, and 
humans (11). All integrins have a basic structure [Figure 5], with an intracellular domain that 
interacts 
 
with 
signals in 
the 
cytoplasm and cytoskeletal elements, a very thin transmembrane domain, and an extracellular 
domain that acts as a receptor for binding to several different molecules, proteins and to relay 
signals between cells (11).  Integrins are distinguished from other integral proteins and receptors 
on the cell surface in that they are bidirectional. This directionality occurs because integrins are 
Figure 5. This schematic shows the structure of a basic integrin. It is transmembrane with the 
intracellular portion highlighted in yellow, and the extracellular portion highlighted in green. 
http://atlasgeneticsoncology.org/Genes/Images/ITGA6Fig2.png 
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able to transmit signals from the extracellular to intracellular domain and vice versa, leading to 
their large roles in immune responses, hemostasis, and overall cell development (11). While 
there are several different types of integrins including 18α and 8β subunits, ITGA6, comprised of 
α6β1 and α6β4, have received special attention due to its role in tumor development (11).  
2.2 ITGA6 in Angiogenesis  
Angiogenesis is the formation of blood vessels that grow from the tumor into the blood 
stream. These blood vessels allow cancer cells to migrate to other organs. In order for 
angiogenesis to occur, proangiogenic factors are essential (5). In a study using hindlimb ischemia 
as a model for peripheral arterial disease (PAD), researchers found ITGA6 levels of expression 
were increased by vascular endothelial growth factor and fibroblast growth factor, two major 
proangiogenic factors (5). Once there were high levels of gene expression, in vitro vascular tube 
formation was enhanced significantly (5). This study concluded that high levels of ITGA6 are 
needed in order to make the blood vessels that stem from the tumor (5). Another study 
researching how angiogenesis occurs found that upregulation of ITGA6 induces the endothelial 
cells to begin vasculogenesis (12). A study using human endothelium cells (EA cells) that 
closely resemble vascular endothelium cells, saw an in vitro formation of a network tube like 
structures, favoring blood vessels and the cellular process, angiogenesis (13). The experiment 
concluded that a G-protein mediated signal was needed in order to form the tube structures. With 
this information, they used pertussin toxin (PT), as means to block the signal, and ultimately 
block angiogenesis (13). However, the researchers saw that PT was able to modestly block 
angiogenesis, but when monoclonal antibodies against ITGA6 were used in the medium, the 
results saw that tube like formation was completely block. Scientists concluding that ITGA6 was 
the protein of most influence in angiogenesis (13). Lastly, an experiment was conducted based 
11 
 
off the previously supported hypothesis that tumors have cells with increased basic fibroblast 
growth factor (bFGF), one molecule that initiates that increased formation of blood vessels (14). 
It was found that in cells with bFGF, there was severe upregulation of α6β1, α6β4 and other 
integrins. These cells also had much better adherence to laminin, fribonection, and collagen 1, 
prime factors thought to have a role in tumor progression (14). The experiment concluded that 
integrins, ITGA6 specifically, led to increase angiogenesis in the endothelial cells (14). In 
conclusion, several research groups have concluded that ITGA6 upregulation plays a significant 
role in angiogenesis; however, scientists have not yet concluded what the increased amounts of 
ITGA6 exactly do in angiogenesis and why normal levels of the same protein do not seem to 
have an impact (14). 
2.3 ITGA6 in Metastasis  
 Metastasis is the dissemination of cancer cells throughout the body via blood vessels 
created during angiogenesis, accounting for approximately 90% of all deaths. In metastasis, 
several researchers have looked in-depth into how ITGA6 is accommodating this largely 
important factor of cancer (15). In a study using human prostate cancer cells and mice as a 
model, researchers knocked down the levels of ITGA6 using a blocking-function antibody (15). 
Their results showed that there was only 40% of the metastatic tumor progression in comparison 
to the control (did not receive the antibody) which saw 80% progression. The study concluded 
that ITGA6 played a role in inducing metastasis (15). A different experiment wanted to discover 
if there was a biomarker for the highly metastatic cancer of the female breast. Their research saw 
that ITGA6 had high levels of expression in brain metastasis (16). They concluded that gene 
profiling to look for the levels of expression for ITGA6 would be an important biomarker for 
early diagnosis for cancer, and hopefully being able to treat the cancer before it begins (16). 
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Another study investigating the effects of metastasis and ITGA6 used esophageal squamous 
cancer cells as a model (17). The results of the experiment concluded there were significant 
levels of ITGA6 and CTHRc1, a protein found at high levels in esophageal cancers, in the cells 
at a rate of 71% (17).  These cells and the expression of the two proteins were compared to the 
levels in normal esophageal cells using immunohistochemistry, and they were able to confirm 
lower levels of expression in the normal cells (17). They also concluded that metastatic cells in 
squamous population also had higher levels, 50% higher, of ITGA6 (17).  They concluded that 
ITGA6 has a large role in metastasis of squamous cancer cells, and may be a potential marker of 
esophageal cancer (17). Lastly, an experiment was conducted to study the role of SNAI1 protein 
and its role in epithelial-mesenchymal transition (EMT), an important factor in metastasis (18). 
Using prostate cancer cell lines, LNCaP and PC3, they saw that knockdown of the SNAI1 protein 
also led to downregulation of ITGA6 which in turn, led to decreased metastasis, and overall 
cancer cell death in both lines (18). Researchers saw that ITGA6 played a large role metastasis 
(18). In conclusion, we have been able to determine that ITGA6 levels can be indicative of 
metastasis, but more research needs to be directed into the correlation of these levels and 
increased progression and susceptibility (18).  
2.4 ITGA6 in Cancer Stem Cells  
Cancer stem cells are self-renewing cells that co-exist within normal cancer cell 
populations and give rise to secondary tumors and relapses in the disease.  In the last factor of 
cancer, CSCs, ITGA6 has also been seen to play a profound role in the stem cell’s ability to 
control angiogenesis and metastasis (19). In an experiment studying the CSCs responsible breast 
cancer’s high metastasis rate, they used an in vitro knockdown approach to reduce gene 
expression of ITGA6. They saw a large decrease in secondary tumors, as well as, the loss of 
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renewal ability in the CSCs (19). Another study in prostate cancer focused on what gave rise to 
the cancer (19). The scientists used gene profiling of progressed human cancer cells to see if 
there were biomarkers of the cancer (19). The profile showed ITGA6 as an important biomarker 
due to its relatively high amounts of gene expression in the entire prostate cancer population and 
in the sub-population of prostate CSCs (20). In CSCs, high levels of ITGA6 have been seen in 
several cancers to play a role in CSC population, but they have not yet seen determined what 
these high levels contribute to (20). In conclusion, research has been able to discovery that 
ITGA6 upregulation, high levels of gene expression plays a role in proangiogenesis, metastasis, 
and cancer stem cell markers (20). 
2.5 Down Regulation of ITGA6  
In another direction, some researchers have even looked into what effects low levels of 
ITGA6 can lead to in cancer progression. While high levels of ITGA6 has been found to promote 
tumor progression, mutations in ITGA6 also can lead to tumor susceptibility and progression 
(21,22). A study in papillary thyroid cancer found that a single missense mutation, a single 
change in a codon that leads to a different mutation, may be responsible for the cancer (21). This 
hypothesis was also supported by a study in prostate cancer in which five different intron single 
nucleotide polymorphisms in the ITGA6 gene led to increased progression in the cancer (22). 
These studies support the notion that even low levels of ITGA6 can lead to cancer progression 
and susceptibility, a contradicting conclusion to high levels also increasing progression (21,22). 
2.6 ITGA6’s Potential Diagnostic/Therapeutic Strategy 
In all, we understand that high levels of ITGA6 can promote any factor of cancer. In 
another aspect of ITGA6, research has suggested that mutated ITGA6 can lead to lower levels of 
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progression in comparison to truncated or cleaved ITGA6.   Cancer researchers know that low 
levels of ITGA6 can also lead to progression and susceptibility, two very contradicting 
statements. However, what we do not yet understand is how exactly both high and low levels 
ITGA6 lead to cancer susceptibility and how a mutated gene can decrease cancer progression.  
 In conclusion, ITGA6’s ability to decrease tumor progression can be examined and 
isolated to potentially provide a therapeutic strategy of minimalizing the cancer or serving as a 
biomarker for the susceptibly to different cancers. With this information, the race to find a cure 
for cancer will be greatly accelerated.  
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3. Hypothesis/Predictions 
 In my study, I plan to study the two questions: 1) will high or low levels of ITGA6 
protein induce tumor metastasis. We predict that increased levels of ITGA6 will induce tumor 
metastasis. 2) will cleaved, extracellular ITGA6 induce tumor metastasis. We hypothesize 
that cleaved ITGA6 will induce tumor metastasis, also. The second question stems from in vitro 
cell culture, where they have seen a cleaving mechanism of the protein. With this mechanism, an 
enzyme cleaves the extracellular portion of the protein, and this product is expressed in the 
microenvironment. A cell culture assay does not allow for the cell-to-cell interactions that are 
present in the tumor microenvironment, and therefore, this mechanism needs to be explored in an 
in vivo model to confirm the mechanism and to determine its effects in tumor progression. We 
pTo explore both questions, we will use a Zebrafish tumor xenograft model. In this model, we 
will transplant human prostate cancer cells into zebrafish embryos, as well as use ITGA6 RNA to 
manipulate the levels of human ITGA6 in the zebrafish.  
 ITGA6 will be used will be regulated in three constructs, full length RNA, truncated 
RNA, and mutated RNA. To study the first question, full length mRNA will be compared to 
embryos with the unchanged or regular levels of ITGA6. Full length mRNA [Figure 6]  
 
 
 
 
Figure 6. In the FL-ITGA6 construct, there 
is an increase of the protein on the cell 
surface. 
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was created by overproducing the extracellular domain of the protein on the surface of the cell. 
Instead of having only one extracellular domain portion, like that of the control embryos, full 
length embryos will have several extracellular domain protein, in order to study these effects on 
tumor progression. We hypothesize increase levels of ITGA6 will induce tumor metastasis and 
overall tumor development. 
To answer the second study, mutated mRNA and truncated mRNA will be used to model 
the in vitro mechanism. Mutated mRNA [Figure 7.A] was translated with a mutation in the 
cleaving site of the enzyme that is believed to cut the extracellular domain of ITGA6. With this 
mutation, the cleaving cannot occur, and the extracellular domain stays attached to the cell 
surface. In truncated mRNA [Figure 7.B] only the extracellular domain of the protein is 
produced, so that there is no ITGA6 on the surface of the cell, and the protein is able to be 
dispersed within the ECM and microenvironment of the tumor. We believe truncated protein will 
increase tumor metastasis and mutated ITGA6 will lead to decreased levels of tumor metastasis 
and overall tumor development. 
 
 
 
 
 
Figure 7.A shows the mutated ITGA6 construct, in which the cleaving site was mutated, so the integrin was fixed 
to the cell surface. 
Figure 7.B The α6p construct only expresses the extracellular component of the integrin, in which it has been 
cleaved. 
   Figure 7.A    Figure 7.B 
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Materials 
4. Cell Culture 
4.1 Inoculation 
Prostate cancer cells, line PC-3, from GeneScript® were obtained from another lab on 
campus. These cells are labeled immortalized cell lines, as they are more homogenous and stable 
than primary cancer cells in in vitro assays. Cell culture must be conducted in a biosafety level 
two lab, with a biosafety cabinet with laminar flow, due to their potential pathogenic properties. 
To begin growing the cells, one bottle of Opti-Mem 1X w/ glutamine w/ HEPES w/o| phenol red 
media, five milliliters of penicillin streptomyocin (P/S), and 50mL of Fetal Bovine Serum (FBS) 
are placed into a 37⁰C water bath for 30 minutes. While the contents are heating, aseptic 
techniques were conducted. The hood was opened half way and sprayed with 70% ethanol. The 
70% ethanol was dried using paper towels, and the appropriate amount of 10 mL and 25 mL 
pipettes for the experiment were obtained and sprayed with 70% ethanol before being placed 
inside of the hood. When the media had 10 minutes left, one vial, containing one milliliter of 
cells, was removed from liquid nitrogen and placed into the 37⁰C water bath. All contents were 
taken out of the water bath after ten minutes, and sprayed with 70% ethanol before being placed 
inside the hood. The growth media was prepared by adding 50mL of FBS and five milliliters of 
P/S to one bottle of growth media. The solution was pipetted up and down, and placed aside. 
Two T-75 cell culture flasks from Corning® were obtained, sprayed with 70% ethanol and 
placed inside the hood. 20mL of media were pipetted into each cell culture flask, and 500uL of 
cells were pipetted into each flask.  The flasks were labeled with the initials, date, and passage 
one, signifying its first splitting from the original line. The flasks were placed into the 37⁰C 
18 
 
incubator. To clean the hood, all contents and pipettes were placed into the biohazard waste bag 
and all glassware was placed into the sharps container. The media was placed in the four degree 
Celsius refrigerator, and the hood was again sprayed with 70% ethanol. The ethanol was dried, 
then hydrogen peroxide was sprayed in the hood. The hood was dried again, closed, and the UV 
light was turned on for one hour. The flasks were checked every 24 hours until confluency 
reached 60-75%, usually spanning five to six days.  
4.2 Harvesting 
When cells have reached confluency, they are ready to be split and used for experiments. 
To begin splitting, growing media and 1X phosphate saline buffer (PBS) were placed into the 
37⁰F water bath for 30 minutes. While the media and PBS heated, aseptic techniques were again 
performed. 70% ethanol was sprayed in the hood and the pipettes were sprayed before being 
placed into the hood. The cell flasks were retrieved from the 37⁰C incubator and sprayed before 
entering the hood. After 20 minutes, 1X trypsin-EDTA was placed into the warm water bath. 
After 10 minutes, all contents were taken out of the water bath, sprayed and put inside the hood. 
A PBS-1X trypsin solution was made by adding 3mL of 1X PBS to 7mL of 1X-trypsin EDTA 
(1.5mL PBS and 3.5mL trypsin for one flask), and they were mixed by pipetting up and down. 
The solution was placed to the side, and the vacuum was used to discard of the previous media 
from each flask. Next, 10mL of PBS was added, and the flasks were rocked back and forth to 
wash all walls. The PBS was discarded, and 5mL of the trypsin-PBS solution was added to each 
flask. The flasks were then placed back into the incubator for 15 minutes. The cells were taken 
out every five minutes and tapped gently on the palm to detach the cells from the bottom. After 
15 minutes, the cells were sprayed and placed back into the hood. Eight milliliters of fresh media 
was added to each flask, then the 13mL solution was transferred to a 15 mL Eppendorf tube. 20 
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mL of fresh media were added to the flasks. The flasks were labeled with initials, date, and 
passage 2 (or corresponding passage) and placed back into the incubator. 
4.3 Counting and Labeling of Cells for Experimentation 
To use the cells for implantation, the 15mL solutions were counted using a 
hemocytometer. 10uL of the solution was pipetted on to the hemocytometer, and each of the four 
quadrants of the hemocytometer were counted, divided by four and multiplied by a factor of 104. 
Next, this concentration was used to determine final volume needed to achieve a desired 
concentration of one million cells per milliliter. This final volume was pipetted from the solution 
into a new falcon tube, and centrifuged at 970 RPM for five minutes. The supernatant was 
discarded and the pellet of cells was broken up. Next, the final volume of R-1 media, media 
without FBS and P/S, was added to the cells. Next, DiI, red in color, was added to the solution 
(5uL per final volume), and pipetted up and down. The solution was put in the incubator for 15 
minutes, and then centrifuged at 500 RCF for two minutes. The supernatant was discarded, pellet 
broken up, and the final volume, calculated using C1V1=C2V2, of fresh media was added to the 
cells. The cells are viable for up to four hours in the incubator. 
4.4 Zebrafish Husbandry 
Zebrafish are a great non-mammalian cancer model for several reasons. Zebrafish are 
widely used as a cancer model, because they can spontaneously develop almost any type of 
cancer that are present in humans (23). They also can mimic the severity of a cancer, such as a 
cancer that shows little metastasis versus a cancer that is highly metastatic. With this, the 
development [Figure 8] of the embryo is ex-utero and transparent which allows for observation 
of the cancer progression in a live model without harming or killing the embryo. Zebrafish are 
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also not adversely affected by genetic knockouts and expression of transgenes, which are 
necessary techniques in regulating levels of human ITGA6 expression (23). Zebrafish are also a 
better tool than other models such as mice, because they are cheaper and can be studied within a 
five day post injection period, while a mouse would have to take one to two months to fully 
develop the cancer. They can also be injected with fluorescent cells [Figure 9] to see the 
progression of 
cancer and ITGA6 
via imaging 
software in vivo. In 
all, a zebrafish 
tumor xenograft 
model would be 
the most efficient 
model to study the 
progression and 
effects of prostate 
cancer and 
different levels of 
ITGA6 of a human.  
Figure 8. The figure 
shows the 
development of the 
zebrafish from 0hpf 
to five days old.  
http://gos.sbc.edu/n/
nv/graphics/nv6.gif 
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 The zebrafish provided in the experiment were obtained from a self-maintained 
laboratory on campus. The fish were kept up to standard using approved protocols, and 
permission was obtained following an IUPAC proposal. To breed the fish to yield fertilized eggs, 
two separate tanks are set up, and eggs are collected the following morning. Transgenic fish of 
the strain, Tg (fli l a: GFP) were used in the making of the xenograft model, as the fli la 
expresses a green fluorescent protein in the blood vessels.  
 
 
 
 
 
 
Figure 9. Panel A shows the injection microscope used in injecting ITGA6 RNA and human prostate 
cancer cells. Panel B shows where the ITGA6 RNA is injected into an embryo at 0hpf. 
A. http://zfish.nichd.nih.gov/Intro%20Page/intro_pix/angio2.jpg 
B. https://i.ytimg.com/vi/7N83MzkzIns/hqdefault.jpg 
 
 
 
 
 
 
A 
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4.5 Manipulation of ITGA6 
4.5.1 RNA Microinjections 
Synthetic RNA constructs were made creating full length, mutated, and truncated forms 
of ITGA6. 
The 
sequences 
for each 
construct 
and pCS2+ 
vector 
[Figure 10]        
were 
determined 
in vitro and 
sent to 
Genscript® 
for 
synthesizing. In order to confirm the presence of each RNA using immunohistochemistry, a 
MYC tag was added to the C-terminus of the protein.  
Figure 10. pCS2+ vector used to make ITGA6 constructs (full length, mutated, and truncated) using 
restriction enzymes ClaI, XbaI, BamHI, and EcoRI. 
http://www.snapgene.com/resources/plasmid_files/image_consortium_plasmids/pCS2+/pCS2+_1x.png 
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The three RNA injections were made to change the protein’s normal structure and 
function. Full length RNA is altered to produce more of the protein on the surface of the cell. 
Truncated RNA mimics the in vitro cleaved protein. With this construct, the protein’s 
transmembrane structure is found in the microenvironment of the tumor, instead of the plasma 
membrane of the cell. The last construct, mutated ITGA6 RNA, mimics the in vitro non-cleaved 
product. With this, the protein’s site of enzymatic cleavage is mutated, allowing the enzyme to 
not be able to cut the protein. In this construct ITGA6 cannot be removed from the cell surface.  
4.5.2 ITGA6 Knockdown 
The “knockdown” approach used in the experiment was the morpholino technique. This 
approach leads to no gene expression of ITGA6 in the zebrafish cell. Morpholino powder was 
ordered from Gene Tools LLC, and resupsended in nuclease free water. The solution was then 
diluted in nuclease free water and dextran tetramethyl-rhodamine. The morpholinos were titrated 
and were then ready to be used in the experiment. 
4.6 Microinjections  
At zero hours post fertilization (hpf), the embryos are injected with their respective RNA 
or antisense RNA. Needles for injection are made using three and one half inch Drummond 
replacement tubes (#3-000-203-g/x) in a Model P-1000 Fleming/Brown Micropipette Puller. The 
solution for each construct is in 0.2% phenol red is pipetted into the needle, and oil is added to 
the needle to remove the remaining air. The tip of the needle was broken using micro tweezers 
and then injected, approximately three nanograms per nanoliter, into the embryo using a 
Nanoject II™ Auto-Nanoliter Injector. The embryos are then placed into the incubator, and will 
be ready in 24 hours for the second round of injections.  
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Next, the cultured prostate cancer cells will be used to inject into the embryo. The cells, 
at a concentration of 1,000,000 cells/mL, were loaded into the microinjection needle. Oil was 
then injected into the needle to remove air, and the tip of the needle was broken using micro 
tweezers. The zebrafish are then taken out of the incubator, and placed into tricane, a light 
anesthetic. The cancer cells are injected into the embryos, and then are washed with embryo 
medium to take away the effects of tricane. The embryos are then placed back into the incubator.  
4.7 Observations and Confocal Imaging 
4.7.1 Observations 
After injections, the embryos are assayed for metastasis and angiogenesis for two days 
(observations beginning when embryos are 48hpf). To conduct the assays, the embryos are taken 
out of the incubator and placed in tricane, a light anesthetic. The embryos are observed for 
angiogenesis looking at the embryos under the GFP 470 filter. This filter is used, because the 
blue fluorescence allows the blood vessels to illuminate green, allowing for easy visualization of 
the red-labeled cancer cells. The Rhodamine filter is used to observe metastasis, as this filter 
fluoresces green and illuminates the cancer cells in red. The embryos are then taken out of 
tricane, washed with embryo medium, and placed back into the incubator. Assays are then 
performed again, approximately 24 hours later, under the same conditions.  
4.7.2 Confocal Imaging  
After observations on the second day, confocal imaging begins. Confocal imaging allows 
for both blue and green fluorescence enabling the visualization of the red cancer cells in the 
green blood vessels. Two embryos showing metastasis and angiogenesis and one without is 
imaged per treatment. To begin confocal imaging, each embryo is live mounted onto a slide. 
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Live mounting is conducted by placing the embryo in tricane, a light anesthetic, for 
approximately one minute, or until it is not moving. It is then pipetted into a drop of methyl 
cellulose that is in the depression of a depression slide. The embryo is manipulated so that the 
body is on its side, with the head pointing to the right. It is then placed in the laser confocal 
microscope. The microscope is set to the 488 wavelength, and a time lapse video of 
approximately one minute and a half is created. The embryo is washed with embryo medium, 
placed back into the incubator, and the next fish was imaged. After all imaging is conducted, the 
embryos are fixed with 4% Paraformaldehyde for preservation.  
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Results and Discussion 
 
 
 
 
 
 
 
 
 
 
Using confocal imaging, we were able to visualize the expression of our ITGA6 
constructs in the embryo. With the FL-ITGA6 embryos, we injected the full length ITGA6 RNA 
into the embryo at 0hpf. After eight hours, we could see the expression of the protein the 
embryo. We expected to see an increased amount of the protein in the embryo. We can see a lot 
of red, signifying the protein, indicating the RNA expressed the correct phenotype. In the α6p 
embryos, we expected to see less of the protein on the cell surface, and more in the 
FL ITGA6 Truncated ITGA6 (α6p) Mutated ITGA6 
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Figure 11. Panel A shows full length ITGA6 with increased protein on the cell surface. Panel B shows only the 
extracellular portion of ITGA6 was produced, and Panel C shows a mutation in the cleavage siting, allowing the 
protein to be non-cleavable. Panel D shows full length ITGA6 expression in an embryo at 8hpf. Panel E expresses 
the cleaved protein in the microenvironment of the 8hpf embryo, and Panel F shows the mutated ITGA6 only on 
the surface of the cells. 
A B 
D E F 
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microenvironment, as we only expressed the extracellular portion of the protein. We saw this 
phenotype in the embryo. Lastly, we injected mutated ITGA6 RNA into the embryo, and we 
expected to see integrin on the surface of the cell only, as we mutated the cleaving site for the 
enzyme. We also saw this expression in the embryo. With these images, we were able to 
conclude that our RNA constructs are expressing the correct phenotype.  
 
 
 
 
 
 
 
In order to create our humanized zebrafish tumor xenograft model, it was imperative to 
use human prostate cancer cells to study the interactions between human integrin alpha 6 and 
human cancer cells. The red flourescences of the cells allowed for clear visiblity of the tumor, 
another feature important in study in vivo tumor progression. 
 
  
A B 
Figure 11. In this panel, image A shows labeled with DiI-red prostate cancer cells used to inject into the 
zebrafish to make the zebrafish tumor xenograft model. Image B shows the same cells under a fluorescence 
light. 
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The above embryos were imaged using confocal imaging. This was an important factor in 
being able to clearly distinguish between metastatic and non-metastatic characteristics of each 
embryo.  
 
 
A. Tumor Xenograft – No Metastasis   B. Tumor Xenograft – Metastasis   
Figure 12. Image A portrays a fish with no metastasis. Panel B shows a fish with metastasis in the trunk.  
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The graph above measures the average percentage of tumor metastasis in five groups, 
with the numbers in parenthesis representing how many where in each group. The control group 
only received human prostate cancer cells as a measure to determine the metastasis of the cancer 
cells without manipulation of ITGA6. The FL-ITGA6 embryos expressed an increased amount 
of the protein on the cell surface. α6p fish expressed only the extracellular portion of the protein, 
and the mutant ITGA6 embryos expressed a mutation that did not allow for the enzyme to 
cleave, and therefore, was rooted to the cell surface. Lastly, we used a morpholino knockdown 
approach in the Itga6 MO embryos to ablate the expression of integrin alpha 6. Using a t-test, we 
compared each group to the control. We found a significant statistical p-value of <.01 when 
comparing FL-ITGA6 to the control, suggesting that increasing ITGA6 induces tumor 
metastasis. However, when comparing α6p to the control, we found a smaller, more statistically 
significant p-value suggesting that truncated ITGA6 also induces tumor metastasis.   
 These results add clarity to what may be occurring in the microenvironment of the tumor. 
When a normal cell has undergone transformation into a cancerous cell, a change in the 
microenvironment allows the cell to lose its adhesion to the epithelial basement membrane. This 
change also enables the cell to invade a blood vessel and metastasis to a new tissue, creating 
secondary tumors. With these results, we suggest an increased amount or cleaved integrin alpha 
 
Figure 13. The graph shows the average amount (%) of metastasis of the embryos from each group. 
The number in bracket signifies how many total embryos were a part of the group. Each construct was 
compared to the control, using a t-test. Significant p-values of <0.01 were found in the FL-ITGA6 and 
α6p (truncated ITGA6) constructs. 
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6 protein in the microenvironment are one of the changes allowing these cells to lose adhesion, 
invade, and metastasize (16, 17, 18). With this, ITGA6 has been identified to be a biomarker 
predicting several different cancers such as stomach, oral, prostate, and several more cancers 
(24,25,26).  
 Looking further into the microenvironment of tumors, we speculated that signaling is the 
major factor that allows for the changes to be able to lose adhesion and metastasizes. When there 
is an increased amount of cleaved ITGA6 on the cell, we believe this allows for first, outside-in 
then inside-out signaling, that allows for these tumorigenic properties. To begin, we believe that 
outside-in signaling begins the changes. This type of signaling allows the cell to sense and 
respond to the changes in their environment (27). The signaling begins with a specific ligand-
binding interaction, resulting in changes in the shape of the integrin (28). This changes allows for 
modified protein interaction sites and increased ligand affinity, transmitting the signal into the 
cell (27,29). We believe the signal the cell receives contains information that changes the 
programming of the cell, leading to changes in the morphology and behavior of the cell. A 
change in the morphology allows for an increased amount of membrane protrusions, making the 
cell spiked and able to penetration surfaces (29). The change in behavior allows the cell to be 
more aggressive and to gain increased motility, important factors in invading and moving 
through a blood vessel.  
 Next, inside-out signaling occurs. This signaling pathway accounts for the ability for the 
cell to regulate the activity of its integrin (27,28). Inside-out signaling occurs when other 
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receptors send signals, activating intracellular signaling pathways. After this, the cytoplasmic 
domain of the beta subunit binds specific cofactors, talin and kindlin, in the cell which activates 
ligand-induced bind sites on the extracellular portion of the protein (28,29). We believe that a 
specific substrate or interaction occurs which releases the enzymes into the extracellular matrix. 
We focused on a particular group of enzymes, metalloproteinases (MMPs), which allows the cell 
to degrade the extracellular matrix as it migrates and metastasizes (27,28,29) 
 To conclude, we believe that when a cell undergoes transformation into the cancer cell, 
changes in integrin alpha 6, that either upregulates it or cleaves it, allows the cell to lose cell 
adhesion to its tissue. Next, both outside-in and inside-out signaling pathways allow for the cell 
to become more aggressive, and move through the extracellular matrix to invade blood vessels 
and metastasize. With this, ITGA6 can be used a biomarker to detect the probability of these 
changes occurring. We believe that combining ITGA6 genetic testing with early diagnosis of 
cancer gives the best chances of completely eradicating or killing the cancer in its early stages. In 
the future, we would like to conduct drug assays with ITGA6 to devise a preventative strategy to 
cancer.  
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